Trial ID or NCT#

NCT02142608

Status

not recruiting iconNOT RECRUITING

Purpose

Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results

Official Title

A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2

Eligibility Criteria

Ages Eligible for Study: 50 Years to 70 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No

Investigator(s)

Geoffrey Sonn
Geoffrey Sonn
Urologic oncologist, Urologist, Urologic specialist, Genitourinary specialist
Assistant Professor of Urology and, by courtesy, of Radiology at the Stanford University Medical Center
James D. Brooks
James D. Brooks
Surgical oncologist, Urologic surgeon
Keith and Jan Hurlbut Professor in the Stanford University School of Medicine
Sanjiv Sam Gambhir, MD, PhD
Amelie Lutz
Amelie Lutz
Diagnostic radiologist, Radiologist
Assistant Professor of Radiology (Musculoskeletal Imaging) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061